Becker’s Healthcare is proud to unveil its 2025 list of hospitals and health systems recognized for excellence in oncology. These leading institutions have earned national distinction for advancing cancer care through groundbreaking research, innovative treatments and transformative clinical trials.
Many of the cancer programs featured hold prestigious National Cancer Institute designations and consistently rank among the nation’s top cancer care providers, as recognized by U.S. News & World Report, Newsweek and other respected ranking organizations. This list highlights cancer centers led by world-renowned experts who are driving innovation, ensuring patient safety, and pushing the boundaries of what’s possible in cancer treatment and research.
Note: This list is not exhaustive, nor is it an endorsement of included hospitals, health systems or associated healthcare providers. Organizations cannot pay for inclusion on this list. Organizations are presented in alphabetical order. We extend a special thank you to Rhoda Weiss for her contributions to this list.
We accepted nominations for this list. Contact Anna Falvey at afalvey@beckershealthcare.com with questions or comments.
AdventHealth–Central Florida Division (Orlando). AdventHealth Cancer Institute in Central Florida is the state’s largest cancer care provider, diagnosing more cancer patients than any health system in the state. It treats over 21,000 patients annually through a comprehensive network of 17 cancer centers. AdventHealth Orlando is listed among U.S. News & World Report‘s “America’s Best Hospitals” for cancer care, earning excellent marks for patient survival, advanced technologies, patient services and more. AdventHealth Orlando also appears on the publication’s top 20 honor roll, with rankings in 11 clinical categories. Boasting over 250 medical, surgical and radiation oncologists, the AdventHealth Cancer Institute delivers subspecialty programs across over 10 disease sites, ensuring highly specialized care. In addition to whole-person care in infusion, radiation therapy, bone marrow transplants and more, the cancer institute is one of Florida’s most active clinical research sites, conducting more than 325 clinical trials annually with over 80 cancer-dedicated research employees. The institute is also first in the state to offer liver histotripsy for advanced liver cancer, and is expanding its immuno-effector cell program with new CAR T treatments, including the first outpatient CAR T program in Central Florida. It is also first in Florida to launch an innovative AI and genetics program to help patients learn their risk of breast cancer.
Advocate Health (Charlotte, N.C.). The Advocate Health cancer national service line is one of the nation’s largest and most comprehensive cancer care networks, treating more than 45,000 new cancer cases annually across 50-plus locations in six states. The program is anchored by an NCI-designated comprehensive cancer center, the Atrium Health Wake Forest Baptist Comprehensive Cancer Center in Winston-Salem, N.C., and offers two NCI community oncology research program sites, enabling participation in over 800 clinical trials and supporting more than 12,000 patients in 2024. With $45 million in annual research funding, Advocate Health combines innovative science with compassionate care, becoming the first in the world to achieve Planetree International “gold certification for excellence in person-centered care”. The system’s groundbreaking initiatives include the nation’s first financial toxicity tumor board, which has saved patients over $400 million in medication and copay costs, and the Carolinas’ only proton beam therapy program. Recognized by Money as one of 2025’s “Best Hospitals for Cancer Care”, Advocate Health leads oncology care through research, technology, and a deep commitment to equity and innovation.
Allina Health (Minneapolis). Established in 2021, Allina Health Cancer Institute has quickly become a regional destination for comprehensive, innovative oncology care. With more than 200 specialists and over 50 active clinical trials, the institute provides access to groundbreaking therapies through partnerships with the Guardian Network, the Metro-Minnesota Community Oncology Research Consortium and other organizations. The institute is pioneering advances in AI for early detection, introducing mobile lung and mammography screening programs that are the first of their kind in Minnesota, and leading in novel therapies such as histotripsy, bispecific T-cell engagers and Pluvicto for advanced prostate cancer. In 2024, the institute received multiple U.S. News & World Report “high performing” designations for cancer surgery. Committed to equity and access, the institute also delivers over $7 million in annual patient financial support through its navigation program.
Atlantic Health (Morristown, N.J.). Atlantic Health’s cancer care line delivers comprehensive, multidisciplinary cancer treatment through its flagship Carol G. Simon Cancer Center at Morristown (N.J.) and Overlook (Summit, N.J.) Medical Centers and across five additional hospital locations. The system manages more than 8,500 new cancer registry cases annually, supported by a network of approximately 250 cancer specialists. As the lead affiliate of the Atlantic Health Cancer Consortium, the state’s only NCI community oncology research program, the system drives innovation in research and care through its breakthrough oncology accelerator in partnership with the Translational Genomics Research Institute. The system operates a phase 1 research program at its Breakthrough Treatment Center, offering access to novel therapies and pioneering trials, including CAR T and other cellular treatments. Atlantic Health is also advancing care through installation of the MEVION S250-FIT proton therapy system, making it one of the first in the world to retrofit an existing vault for proton therapy. The cancer care program receives more than $4 million in annual research funding and earns consistent U.S. News & World Report recognition for excellence in cancer surgery and specialty care.
Banner MD Anderson Cancer Center (Gilbert, Ariz.). Partnering with the nation’s leading cancer center, Banner MD Anderson Cancer Center treated over 51,000 patients in 2024 alone. The cancer center integrates the latest research, education and prevention using the same protocols and practice standards at MD Anderson Cancer Center in Houston. The evidence-based, multidisciplinary approach brings together 325 physicians and other clinical experts from all cancer specialties at five Arizona and two Northern Colorado cancer center sites to provide treatment plans tailored to each patient’s unique cancer type and needs. Leading-edge therapies include immunotherapy, targeted therapy, stereotactic body radiation therapy, and nearly 225 clinical trials that explore new treatment modalities and therapies not widely available. It is one of a small number of cancer centers offering tumor-infiltrating lymphocyte cellular immunotherapy using a patient’s immune cells to fight cancer, as well as histotripsy focused ultrasound to treat both malignant and benign liver tumors. In addition, holistic care addresses physical, emotional and psychological needs, as well as nutrition counseling, pain management and psychological support. In 2024, the program launched a mobile mammography unit and opened a new community of homes designated for patients undergoing treatment and their loved ones, helping to eliminate the financial burdens of travel and hotel stays. Robust community outreach and education programs raise awareness about prevention, screening and treatment.
Baptist Health South Florida (Coral Gables). Baptist Health Cancer Care, which includes Miami Cancer Institute and the Christine E. Lynn Cancer Institute, is the largest cancer program in South Florida and ranks among the top 10% of cancer programs nationwide, according to U.S. News & World Report. The institutes offer comprehensive, multidisciplinary cancer care featuring all major radiation modalities like proton therapy, alongside advanced surgical and precision oncology programs. Miami Cancer Institute is also the only South Florida member of the Memorial Sloan Kettering Cancer Alliance, ensuring patients have access to nationally recognized standards of care and innovative clinical trials. The system continues to expand its leading-edge capabilities with a new proton therapy center at Lynn Cancer Institute and the Al and Jane Nahmad Women’s Cancer Center, set to open in 2026. Baptist Health Cancer Care was recognized with 11 “high performing” ratings by U.S. News & World Report for excellence in multiple cancer specialties for 2025-26.
Baylor Scott & White (Dallas). Baylor Scott & White features a comprehensive cancer program, delivering coordinated, state-of-the-art oncology services across Texas. The Baylor Scott & White Charles A. Sammons Cancer Center in Dallas is nationally ranked among the best cancer hospitals and treats a high volume of patients with various types of cancer. The program’s multidisciplinary model brings together medical, surgical and radiation oncologists, along with subspecialists, to tailor personalized treatment plans while ensuring seamless transitions among care settings. They emphasize access, innovation and supportive services, offering advanced diagnostics, molecular profiling, clinical trials and integrative support like nutrition, rehabilitation, genetic counseling and palliative care. The network’s broad geographic footprint ensures that patients receive high-quality care close to home, while benefiting from centralized resources and expertise. Baylor Scott & White is also committed to research and the translation of new therapies, investing in clinical trials and collaborations that accelerate access to next-generation treatments. The program’s integrated approach combines expert clinicians, advanced technology, research and patient support.
Beth Israel Deaconess Medical Center (Boston). The cancer center at Beth Israel Deaconess Medical Center is nationally recognized for excellence in patient-centered cancer care and pioneering research that has transformed cancer treatment worldwide. A founding member of the Dana-Farber/Harvard Cancer Center and a major recipient of National Institutes of Health funding, the center integrates breakthrough research in ribonucleic acid medicine, immunotherapy, organoid modeling and co-clinical trials to advance personalized therapies. The Leon V. and Marilyn L. Rosenberg Clinical Cancer Center is the only program in Massachusetts, and one of only 34 nationwide, to earn the Commission on Cancer’s “Outstanding Achievement Award”. Through multidisciplinary clinics, patients meet all key specialists in one visit, ensuring coordinated, individualized care, while robust support services sustain patients and families through every stage of treatment. In partnership with its regional network across Eastern Massachusetts, the center delivers seamless access to advanced diagnostics, clinical trials and leading-edge therapies, uniting academic discovery with compassionate, community-based care.
Boston Medical Center. Boston Medical Center’s cancer center delivers comprehensive, equity-focused cancer care to more than 8,000 patients annually through over 60,000 visits. Recognized by U.S. News & World Report as “high performing” in cancer care in 2024 and 2025 and ranked among “America’s Best Cancer Hospitals” by Newsweek, the medical center provides advanced treatment options across 10 specialized programs, including hematologic, breast, gastrointestinal and thoracic oncology. The center is a national leader in health equity and innovation, offering pioneering cellular therapies such as first-line CAR T-cell therapy for multiple myeloma, a groundbreaking approach that expands access for historically underserved populations. In 2024, the medical center launched a 3,000-square-foot clinical research unit, the first of its kind for an essential hospital in Boston, to increase participation in early-phase clinical trials. Through its health equity accelerator, the center is narrowing racial and socioeconomic gaps in cancer prevention, screening and treatment.
Carilion Clinic (Roanoke, Va.). Carilion Clinic delivers cancer care across western Virginia and West Virginia, supported by partnerships with Virginia Tech and Radford University to advance research, education and clinical innovation. The program is accredited by the American College of Surgeons’ Commission on Cancer and recognized by U.S. News & World Report as “high performing” in multiple cancer specialties, including colon, lung, gynecologic, prostate and hematologic cancers. Carilion recently broke ground on the seven-story, 257,000-square-foot Carilion Taubman Cancer Center, funded in part by a $25 million philanthropic gift, which will expand access to precision medicine, clinical trials and next-generation technologies. The system also introduced the Crystal Spring Tower, a 500,000-square-foot expansion enhancing emergency and trauma services. With 30 active clinical trials, over $1.4 million in oncology research funding, and innovative quality programs like the “GI Big Board” for real-time care coordination, Carilion Clinic elevates regional cancer care by blending academic collaboration, advanced technology and deeply personalized patient support.
Cedars-Sinai (Los Angeles). Cedars-Sinai’s cancer line delivers comprehensive, patient-centered care for more than 60 types of cancer, uniting expert oncologists, surgeons and researchers across the greater Los Angeles area. Ranked No. 18 nationally for cancer care by U.S. News & World Report for 2025–2026, the program combines leading-edge science with personalized treatment. Patients benefit from access to more than 200 active clinical trials exploring novel therapies, diagnostics and technologies that advance cancer care. Specialized programs in hematology and cellular therapy, orthopaedic oncology, breast and women’s cancers, and cardio-oncology ensure tailored expertise across every cancer subtype. Cedars-Sinai’s multidisciplinary teams emphasize whole-patient support through genetic counseling, survivorship services and family-centered care. Cedars-Sinai Cancer utilizes world-renowned specialists and a deep commitment to innovation to achieve excellence in oncology research, treatment and patient experience.
Children’s Health (Dallas). The Pauline Allen Gill Center for Cancer and Blood Disorders at Children’s Health is the largest pediatric cancer and blood disorders program in North Texas, diagnosing up to 400 new cancer cases and 1,600 hematology cases each year. Ranked No. 15 in pediatric oncology by U.S. News & World Report for 2025-26, the center delivers world-class care through a team of 42 UT Southwestern faculty physicians and scientists and serves as the pediatric arm of the National Cancer Institute-designated Harold C. Simmons Comprehensive Cancer Center. The program continues to expand access through major investments, including a new $5 billion Dallas pediatric campus and the recently opened Plano (Texas) tower, which brings advanced hematology-oncology services closer to families. Research leadership is a defining strength, with 155 active clinical studies and national influence in early-phase trials, immunotherapy and cellular therapy. Recent innovations span groundbreaking microbiome research, national VITAS immunochemotherapy trials for relapsed solid tumors, and advances that may reshape infection prevention and immunotherapy effectiveness. The program boasts exceptional survival rates and industry-leading quality metrics.
Children’s Hospital Colorado (Aurora). The Center for Cancer and Blood Disorders at Children’s Hospital Colorado is ranked No. 4 in the nation by U.S. News & World Report for 2025-26 and recognized as the top pediatric cancer program in the Rocky Mountain region. As part of an NCI-designated comprehensive cancer center, the program leads more than 300 clinical trials and 100 research studies annually, achieving cure rates that consistently exceed national averages. With a multidisciplinary team of nearly 100 specialists and over 1,500 bone marrow transplants performed in the past 25 years, the center is a national leader in pediatric neuro-oncology, hematology and transplant innovation. Recent breakthroughs include participation in the EDIT-301 gene-editing clinical trial for sickle cell disease, leadership in the pediatric health equity consortium and multimodal initiatives to reduce C. difficile infections. Children’s Hospital Colorado is supported by over $15 million in National Institutes of Health and foundation funding.
Children’s Hospital of Philadelphia. The cancer center at Children’s Hospital of Philadelphia comprises a multidisciplinary team of more than 1,000 experts who provide innovative treatments and personalized care to more than 5,600 patients per year. Consistently ranked among the top pediatric cancer centers in the nation by U.S. News & World Report and Newsweek, the center has nearly 600 active clinical trials, more than any other U.S. pediatric hospital, and 19 highly specialized clinical programs that offer a full array of treatment options and innovative care for all types of childhood cancers and related conditions. It is also home to the Center for Precision Medicine for High-Risk Pediatric Cancer, which develops individualized treatment plans based on patients’ unique vulnerabilities and therapeutic markers. In 2012, the hospital successfully treated the first pediatric gene therapy patient with CAR T-cell therapy for relapsed leukemia, directly leading to the first FDA-approved gene therapy in the U.S. in 2017. Since that time, the hospital has treated more than 600 children using this therapy, more than any other hospital. Children’s Hospital of Philadelphia leads the field of cell and gene therapy with breakthroughs, including FDA approvals for the first two gene therapies for sickle cell disease.
Cincinnati Children’s. Ranked the No. 1 pediatric cancer program in the nation by U.S. News & World Report for 2024–25, Cincinnati Children’s Cancer and Blood Diseases Institute is a global leader in pediatric cancer and hematology research, innovation and care. The institute brings together more than 100 physician-scientists and offers one of the world’s most comprehensive pediatric oncology programs, performing over 2,400 bone marrow transplants and leading the nation in the development of new anti-cancer drugs for children. Its pioneering research has led to FDA approvals for therapies such as Selumetinib for neurofibromatosis and Vyxeos for acute myeloid leukemia, and it remains at the forefront of immunotherapy and virus-specific T-cell treatments. The institute is home to one of the largest survivorship programs and vascular malformation centers in the U.S., with more than 1,200 T-cell infusions performed. Through initiatives like the Advanced Leukemia Therapies and Research Center and the ENGRAFT Learning Health Network, Cincinnati Children’s is improving survival, reducing treatment toxicity, and advancing equitable, data-driven innovations for children and young adults worldwide.
City of Hope (Duarte, Calif.). City of Hope is one of the nation’s largest organizations for advanced cancer research and treatments, serving five major metropolitan areas across the U.S. With a robust national network of over 550 physicians and 1,000 researchers, City of Hope is recognized for its pioneering work in cancer treatment and research. Its Duarte campus features a robust good manufacturing practice infrastructure, designed to support the rapid translation of innovative therapies from research to clinical trials. The organization has led breakthroughs in therapies such as CAR T-cell treatments and biotherapeutics that enhance immunotherapy. It operates one of the largest bone marrow transplant programs in the country, having performed more than 20,000 transplants to date, and conducts more than 730 clinical trials annually. Recent innovations include a novel liquid biopsy test for lung cancer and a highly accurate early detection test for pancreatic cancer. City of Hope is advancing research in microbiome science, AI-driven diagnostics and remote robotic surgery, and has been developing a groundbreaking biorepository to support personalized cancer care and improve outcomes. An NCI-designated cancer center, City of Hope Comprehensive Cancer Center is ranked among the top 10 cancer care centers in the nation by U.S. News & World Report.
Cleveland Clinic. Cleveland Clinic Cancer Center delivers world-class, multidisciplinary care informed by internationally recognized research and innovation. As part of the NCI-designated and National Comprehensive Cancer Network-member Case Comprehensive Cancer Center, the program brings together more than 800 physicians, researchers, nurses and technicians across the Taussig Cancer Institute, 25 specialty institutes, and regional and international sites. Cleveland Clinic’s integrated model ensures patients benefit from rapid, coordinated access to leading experts in surgical, medical and radiation oncology, supported by robust clinical trials and precision medicine programs. Accredited by the American College of Surgeons’ Commission on Cancer with commendation in all eligible areas, the center offers care for nearly every cancer type, including complex and rare diseases. Its research teams are pioneering novel therapeutics and translational studies that redefine cancer prevention and treatment strategies.
Connecticut Children’s (Hartford). Connecticut Children’s nationally recognized Center for Cancer & Blood Disorders is an innovative leader in pediatric oncology and hematology. In partnership with the National Pediatric Cancer Foundation’s Sunshine Project, it is leading a multi-site clinical trial using Digoxin for recurrent medulloblastoma, which opened in September 2024 across the U.S. Its cancer predisposition program, launched in 2025, brings together oncology and genetics experts in a new multidisciplinary clinic focused on risk assessment and early detection. The center now offers access to more than 100 active clinical trials through the Children’s Oncology Group, Beat Childhood Cancer Research Consortium and the Sunshine Project. The center’s survivorship program expanded by 30% in 2025, supporting long-term health and wellness for childhood cancer survivors. The center is known for its provision of personalized medicine, psychosocial support and translational research.
Dana-Farber Cancer Institute (Boston). Dana-Farber Cancer Institute is internationally recognized as a leader in cancer care and research. With a history going back to the father of modern chemotherapy, the NCI-designated comprehensive cancer center provides expert equitable care, while advancing the understanding, diagnosis, treatment and prevention of cancer and related diseases. Dana-Farber is the only hospital ranked nationally in the top three by U.S. News & World Report in both adult and pediatric cancer, and records 600,000 outpatient visits annually while supporting more than 1,100 clinical trials. Dana-Farber’s faculty publish more than 1,200 scientific articles each year, driving advances that shape cancer research and care around the world. A recent study published by the National Bureau of Economic Research shows that Dana-Farber Cancer Institute has the highest scientific output per researcher of any institution in the world. The City of Boston recently approved Dana-Farber’s plans to build a new 300-bed adult inpatient hospital, which will further improve patient experience and access to care.
Dartmouth Health (Lebanon, N.H.). Dartmouth Cancer Center, part of Dartmouth Health and the Geisel School of Medicine at Dartmouth, is an NCI-designated comprehensive cancer center that has been recognized nationally for both advanced treatment and pioneering research. The center coordinates personalized, multidisciplinary care for patients across New Hampshire and Vermont through its main campus in Lebanon and regional partner sites. With over 135 research scientists leading 250 active projects and securing more than $68 million annually in funding, Dartmouth Cancer Center is at the forefront of cancer prevention, early detection and innovative therapy development. Its investigators are global leaders in cancer prevention and control, focusing on nutrition, environmental exposure and behavioral risk reduction. Named a 2024 Press Ganey “Human Experience Pinnacle of Excellence Award” recipient, the center is also distinguished for its compassionate, patient-centered care that prioritizes both outcomes and quality of life.
The DeTar Hospital (Victoria, Texas). DeTar Hospital Cancer Center, opened in January 2023, houses physician care, infusion therapy, advanced imaging and radiation therapy in one convenient location and is only the second dedicated cancer center across the South Texas Crossroads area. The 12,000-square-foot new center utilizes design techniques that improve the delivery of care and enhance the patient experience. In addition to imaging and radiation therapy areas, the center features 11 patient exam rooms and 15 chemo and immunotherapy infusion bays, a positron emission tomography scan machine for cancer imaging and a medical linear accelerator. The scanner assists in pinpointing the precise location of the cancer so that radiation treatment can be delivered to the affected cells while limiting damage to healthy cells and nearby organs. Oncologists at the center frequently work with patients who see a primary oncologist in another community to help ease the physical, emotional and financial burden of traveling hours away on a daily basis.
Duke University Health System (Durham, N.C.). An NCI-designated comprehensive cancer center, Duke Cancer Institute integrates personalized medicine, groundbreaking research, clinical trials and comprehensive support services to serve more than 40,000 new patients annually in eight locations. The Duke Cancer Institute is a national leader in immunotherapy and precision oncology, delivering customized care pathways and next-generation treatments tailored to each patient. Among its recent game-changing breakthroughs are the development of FDA-approved isocitrate dehydrogenase inhibitors for patients with low-grade glioma and the use of AI to predict the need for hormonal therapy in prostate cancer. Understanding time is critical in cancer care, rapid access is a top priority and the institute offers same-day and next-day appointments for newly diagnosed patients. This 48-hour appointment availability reflects a deep commitment to timely intervention, helping patients begin their treatment journey without delay and significantly enhancing both satisfaction and outcomes. In addition, its population health initiatives broaden outreach across North Carolina, improving access to screenings and navigation services in rural and underserved areas. The institute is home to more than 400 researchers and physicians, 200 active clinical trials and more than $115 million in cancer research funding.
Emory Healthcare (Atlanta). Winship Cancer Institute is Georgia’s only NCI-designated comprehensive cancer center, offering world-class, research-driven cancer care and access to the latest therapies. As part of Emory Healthcare, the institute provides innovative therapies for both common and rare cancers. Its multidisciplinary teams include physicians, nurses, nutritionists and social workers who address every aspect of a patient’s wellbeing from diagnosis through survivorship. With hundreds of clinical trials available, the institute gives patients early access to breakthrough treatments years before they’re widely available, improving outcomes and offering hope to families across the Southeast. Through partnerships with organizations like the Arthur M. Blank Family Foundation and New York City-based Mount Sinai Health System, the institute is also expanding access to early detection programs like mobile prostate cancer screening to reduce health disparities statewide.
Franciscan Missionaries of Our Lady Health System (Baton Rouge, La.). Franciscan Missionaries of Our Lady Health System delivers comprehensive, patient-centered cancer care across Louisiana and Mississippi through its network of leading centers, including the JD Moncus Cancer Center, Our Lady of the Lake Cancer Institute, St. Dominic’s Cancer Center, St. Francis Cancer Center and the St. Jude Affiliate Clinic at Our Lady of the Lake Children’s Health. The system’s multidisciplinary team of oncologists, surgeons, radiologists and support specialists provides advanced care for all major cancer types, including lung, colorectal, reproductive and skin cancers. Patients have access to innovative treatments, cutting-edge clinical trials, and personalized nutrition and survivorship programs that address both physical and emotional health. With an emphasis on local access to nationally recognized care, the system eliminates the need for patients to travel out of state for world-class oncology services. Beyond treatment, Franciscan Missionaries of Our Lady Health System supports patients and survivors through programs such as “Camp Bluebird” and personalized survivorship counseling, helping individuals thrive in life after cancer while maintaining a focus on faith, community and whole-person healing.
Fred Hutchinson Cancer Center and UW Medicine (Seattle). Fred Hutchinson Cancer Center and UW Medicine are independent organizations that work as a clinically integrated team to bring adult oncology patients the specialized focus of a leading independent cancer center, plus the comprehensive services of a top-ranked health system. With both organizations known globally for medical discoveries, patients have access to the latest research, treatment options and clinical trials for all types of cancers. Many researchers and clinicians have faculty roles at both organizations. Fred Hutch is the only NCI-designated cancer center in Washington state. Its Nobel-prize winning work created bone marrow transplantation, the first example of using the human immune system to cure cancer. As science uncovers increasing connections between cancer, viruses and immune responses, both organizations are well-known for their infectious disease research and vaccine trial expertise, including their crucial role in coordination of the nation’s Covid-19 vaccine trials.
Grandview Medical Center (Birmingham, Ala.). The first cancer center in Alabama to receive center of excellence designation from the National Pancreas Foundation, Grandview Medical Center’s cancer center houses both radiation and medical oncology, with on-site positron emission tomography/CT scan services and dedicated navigation for breast and thoracic oncology. Three hepato-pancreato-biliary surgeons support its pancreatic center, and five advanced-trained gastroenterologists support its advanced endoscopy center. The hospital is also home to an accredited women’s imaging program led by a fellowship-trained breast radiologist, offering 3D mammography, guided biopsies and a multidisciplinary breast health team. Grandview continues to invest in additional service lines to account for the growing need for oncology services and to better serve the Birmingham community, including the recent completion of a $6 million expansion of its on-site gastroenterology ambulatory surgery center and a $1 million upgrade of its center for mammography and biopsy diagnostic.
Geisinger (Danville, Pa.). Geisinger provides advanced, personalized hematology and oncology care to more than 5,000 patients annually across 11 locations systemwide. Patients have access to advanced treatments and technology including genetic testing, chemotherapy and radiation therapy such as CyberKnife and CAR T-cell therapy, all without leaving their region. Geisinger Medical Center in Danville and Geisinger Wyoming Valley Medical Center in Wilkes-Barre, Pa. are accredited by the American College of Surgeons Commission on Cancer and achieved “Quality Oncology Practice Initiative” certification from the American Society of Clinical Oncology. Geisinger oncology services and education programs have accreditations for its bone marrow transplant program, micrographic surgery and dermatologic oncology fellowship, and oncology pharmacy residency program. Geisinger’s innovative, AI-powered “System to Track Abnormalities of Importance Reliably” program detects cancer earlier as part of its lung cancer screening program. Geisinger also participates in nearly 100 national clinical research trials and studies, offering patients the latest treatments.
Geisinger Janet Weis Children’s Hospital (Danville, Pa.). Geisinger is the only health system in northeast and central Pennsylvania to offer pediatric hematology and oncology services through its Janet Weis Children’s Hospital. It is a member of Children’s Oncology Group, which performs national and international trials to develop leading-edge treatments, improve outcomes and minimize side effects with quality survival of childhood cancer care. Janet Weis Children’s Hospital’s affiliation with Children’s Hospital of Philadelphia provides additional expertise in rare and complex cases, while allowing families to stay close to home for treatment. The Janet Weis Children’s Hospital team of certified child life specialists help children and families cope by using developmentally appropriate play to help explain conditions and treatments and to offer diversions during hospital stays and procedures. With a leading adult cancer program on the same hospital campus, it is one of a small number of health systems offering adult and pediatric cancer care in one location.
Hackensack Meridian Health (Edison, N.J.). John Theurer Cancer Center, the flagship cancer program of Hackensack Meridian Health, is the top-ranked cancer center in New Jersey and among the top 50 nationwide, according to U.S. News & World Report‘s 2025–2026 rankings. As part of a partnership with Washington, D.C.-based Georgetown Lombardi Comprehensive Cancer Center, an NCI-designated comprehensive cancer center, John Theurer Cancer Center delivers advanced, subspecialized care across 16 divisions encompassing every cancer type. It is home to one of the nation’s largest blood cancer and cellular therapy programs, with more than 12,000 bone marrow transplants and over 1,250 CAR T-cell treatments performed to date. The center’s expanding precision oncology and immunotherapy platforms, robotics programs, and phase 1 clinical trials underscore its leadership in innovation. The center oversees more than 450 active trials, including 30 in cell therapy, generating over $30 million in annual research funding. Recognized for excellence across multiple oncology disciplines and leading-edge technologies such as RefleXion biology-guided radiotherapy and ZAP-X gyroscopic radiosurgery, the center supports Hackensack Meridian Health’s mission to redefine cancer care through discovery, collaboration and compassionate expertise.
Hartford (Conn.) HealthCare. The Hartford HealthCare Cancer Institute provides comprehensive, nationally accredited cancer care across Connecticut, supported by more than 350 oncology specialists. In 2025, the system celebrated the 10th anniversary of its flagship cancer institute at the Hospital of Central Connecticut in New Britain, marking a decade of transformative patient-centered innovation. As the nation’s first Memorial Sloan Kettering Care Partner, Hartford HealthCare delivers New York City-based MSK’s world-class standards of care throughout its network. The system is leading statewide advances in screening and early detection, including a 171% increase in lung screenings since 2019, a high-risk pancreatic cancer program and a new mobile mammography unit. Hartford HealthCare also opened the state’s first Varian Ethos radiation therapy system at its new 25,000-square-foot Fairfield (Conn.) Cancer Center and continues to advance proton therapy development in partnership with Yale New Haven (Conn.) Health. Hartford HealthCare is accredited by the Commission on Cancer as Connecticut’s only integrated network cancer program.
Houston Methodist. The Houston Methodist Neal Cancer Center treats approximately 7,000 new cancer cases each year, offering care across eight locations throughout Greater Houston. Ranked No. 19 nationally for cancer care by U.S. News & World Report and recognized as an “honor roll” hospital, Houston Methodist is distinguished for its pioneering research, innovative therapies and compassionate multidisciplinary care. Teams of oncologists, surgeons, radiologists, pathologists and genetic counselors collaborate to create personalized treatment plans for both common and rare cancers, supported by advanced diagnostic technology and translational research. The center’s extensive clinical trial program provides patients access to promising therapies for cancers including brain, breast, lung, pancreatic and hematologic malignancies. Guided by a mission to prevent, diagnose and treat cancer with precision and empathy, the Neal Cancer Center pairs nationally recognized expertise with a whole-person approach to healing, recovery and survivorship.
IU Health (Indianapolis). The IU Health Simon Cancer Center, Indiana’s only NCI-designated comprehensive cancer center, provides advanced, research-driven cancer care in partnership with the Indiana University School of Medicine. Established in 1992, the center offers leading-edge prevention, diagnosis and treatment options, including precision genomics, immunotherapy, and innovative radiation and surgical oncology techniques. Recognized as a U.S. News & World Report “high performing” hospital for cancer care, the center’s multidisciplinary teams, which include physicians, nurses, dietitians, social workers and spiritual care experts, deliver personalized care tailored to each patient’s needs. The center’s “CompleteLife” program integrates art, massage, music and yoga therapy to support patients’ physical and emotional wellbeing. Through extensive clinical trials and genomic testing, IU Health Simon Cancer Center pioneers personalized medicine and drives cancer research that improves survival, outcomes and quality of life for patients across Indiana and beyond.
Inova (Falls Church, Va.). Inova Schar Cancer Institute, with access points across all five Inova hospitals, provides top-tier cancer care backed by research and innovation. The institute cares for more than 65,000 unique patients annually and offers over 160 active oncology clinical trials, providing access to cutting-edge therapies such as proton therapy, stem cell transplantation, CAR T-cell therapy and immunotherapy. Its Inova Saville Cancer Screening and Prevention Center, the region’s first and only comprehensive prevention facility, leads efforts in early detection, genetic testing and tailored cancer risk reduction. Inova’s “Peterson Life with Cancer” program provides free, holistic support through more than 130 monthly classes and services focused on mental health, nutrition and wellness. The institute boasts nationally recognized accreditations from the American College of Surgeons and American Society for Radiation Oncology, as well as groundbreaking research collaborations with Advanced Research Projects Agency for Health and the Cancer Screening Research Network.
Jefferson Health (Philadelphia). The Sidney Kimmel Comprehensive Cancer Center at Jefferson Health is an NCI-designated comprehensive cancer center, known for excellence in research, prevention and multidisciplinary cancer care. Accredited by the American College of Surgeons Commission on Cancer, the center delivers high-quality treatment supported by more than 250 active clinical trials and over 1,400 annual accruals. Its innovative “same day/next day cancer care” program provides patients with rapid telehealth access to oncology specialists within 48 hours of diagnosis, ensuring timely care and emotional support during a critical period. Jefferson’s integration with Allentown, Pa.-based Lehigh Valley Health Network in 2024 expanded its cancer expertise across 32 hospitals and 700 care sites, bringing CAR T therapy, stem cell transplantation, adaptive radiation therapy, and novel treatments such as histotripsy and hepatic artery infusion to new regions. With $77 million in research funding and recent recognition from the American Society of Hematology and American Society of Clinical Oncology for quality transformation and patient-centered care, Jefferson continues to reduce readmissions and improve survival outcomes.
Johns Hopkins Medicine (Baltimore). The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins is a global leader in translational oncology, uniting pioneering research and clinical expertise to deliver some of the world’s most advanced cancer therapies. As an NCI-designated comprehensive cancer center, the center’s clinicians and scientists collaborate closely to accelerate the transfer of laboratory discoveries like CAR T cell therapy and novel immunotherapies into patient care. The center encompasses leading programs in bone marrow transplantation, new drug development and precision oncology through the Bloomberg~Kimmel Institute for Cancer Immunotherapy and the Johns Hopkins Proton Therapy Center. Patients benefit from a robust genetics program offering early detection, prevention and counseling for hereditary cancers. Comprehensive patient and family services, including survivorship and palliative care programs, support holistic treatment. Johns Hopkins offers multiple care sites across the region, as well as state-of-the-art facilities such as the Weinberg and Viragh Cancer Buildings.
Karmanos Cancer Institute (Detroit). The Karmanos Cancer Institute, part of Grand Blanc, Mich.-based McLaren Health Care, is the only NCI-designated comprehensive cancer center in metro Detroit. Dedicated solely to cancer care, Karmanos brings together more than 300 faculty experts and 1,000 staff across 18 locations in Michigan and northern Ohio to deliver leading-edge treatment. Its 15 multidisciplinary teams specialize in every major cancer type, ensuring each patient receives a precise diagnosis and personalized therapy plan from specialists devoted to their specific disease. With one of the nation’s largest clinical trial programs, offering access to over 250 groundbreaking treatments, Karmanos provides patients opportunities to benefit now from novel therapies that would otherwise be unavailable to them. Partnered with Wayne State University School of Medicine, the institute drives scientific innovation through more than 700 cancer-specific research programs annually.
Keck Medicine of USC (Los Angeles). The USC Norris Comprehensive Cancer Center, part of Keck Medicine of USC, is one of the nation’s original NCI-designated comprehensive cancer centers and has maintained this designation since 1973. With more than 200 scientists and clinicians from across six USC schools, USC Norris integrates basic, translational, clinical and population science to advance cancer prevention, treatment and health equity. Its teams deliver care at the 60-bed USC Norris Cancer Hospital, as well as at outpatient centers throughout Los Angeles and Orange County, Calif. The center’s research has produced major advances in understanding the genetic drivers of cancer and in developing novel diagnostics and targeted therapies. Recent innovations include a 91% accurate blood test for early ovarian cancer detection, a predictive blood test for breast cancer recurrence, and the identification of 11 genes linked to aggressive prostate cancer through one of the largest genetic studies of its kind. Supported by major grants from the Ralph Lauren Corporate Foundation, the National Cancer Institute and Stand Up To Cancer, USC Norris leads discoveries that reduce cancer disparities and improve outcomes for diverse populations. The USC Norris Cancer Hospital has also been recognized with the Leapfrog “Top Teaching Hospital” award for four consecutive years.
Loyola Medicine (Maywood, Ill.). Loyola Medicine’s Cardinal Bernardin Cancer Center is a nationally recognized leader in cancer care, innovation and research, bringing together more than 100 oncology specialists who provide comprehensive, multidisciplinary treatment for nearly every type of cancer. The center integrates diagnosis, treatment and support under one roof, offering advanced therapies such as intraoperative radiation, hyperthermia and leading-edge brachytherapy. Loyola was the first in Illinois to introduce several transformative technologies, including the Paxman scalp cooling system and MRIdian Linac MRI-guided radiation therapy. Its adult bone marrow and stem cell program is accredited by the Foundation for Accreditation of Cellular Therapy and holds Blue Distinction Center+ status. Whole-person care is emphasized through the Coleman Foundation Image Renewal Center and the Jim and Jane Miller Patient Navigation Program, both designed to support patients throughout their cancer journey. The system boasts continued clinical innovation that includes real-time adaptive radiation via the Varian Ethos system.
M Health Fairview (Minneapolis). Partnering with the University of Minnesota’s Masonic Cancer Center, an NCI–designated comprehensive cancer center, M Health Fairview delivers world-class, research-driven cancer care to patients across the Twin Cities and beyond. Celebrating 30 years of leadership in cancer discovery and care, the Masonic Cancer Center brings together nationally recognized experts in prevention, detection and treatment, offering access to more than 225 clinical trials spanning over 100 cancer types. Through its integrated network of hospitals and specialty clinics, M Health Fairview provides advanced therapies including radiotheranostics, minimally invasive interventional oncology, precision radiation therapy, and cutting-edge surgical and gynecologic oncology. Patients benefit from a personalized, multidisciplinary approach that extends from pediatric to adult care, with comprehensive support services such as cancer rehabilitation, social work and survivorship programs.
MUSC Health (Charleston, S.C.). MUSC Hollings Cancer Center, part of the Medical University of South Carolina, is the only NCI-designated cancer center in South Carolina. As a leader in cancer research, prevention and patient care, Hollings is home to more than 150 scientists and 120 physicians across 60 subspecialties who are advancing discoveries from the lab to the bedside. The center manages over $50 million in annual research funding and offers more than 200 active clinical trials, translating cutting-edge science into innovative treatments and improved outcomes for patients statewide. The cancer center was recognized by U.S. News & World Report as a “high performing” for cancer care and honored with Magnet designation for nursing excellence. Through statewide outreach, education and a focus on underserved populations, Hollings is reducing the burden of cancer for South Carolinians.
Mass General Brigham (Boston). Mass General Brigham’s cancer institute is anchored by its founding academic medical centers, Massachusetts General Hospital and Brigham and Women’s. Both were ranked among the top five hospitals for cancer care by U.S. News & World Report. Mass General Brigham Cancer Institute features more than 2,000 dedicated cancer subspecialists who receive more than 600,000 ambulatory patient visits each year. The system performs the most cancer surgeries in New England, with its surgical oncologists performing more than 25,000 cancer surgeries and procedures annually. With $442 million in annual cancer research funding and more than 1,000 clinical trials annually, Mass General Brigham Cancer Institute offers research-infused care across 26 sites in its system for close-to-home patient care. The system continues to invest in cancer care infrastructure, including renovation of the Hale Building at Brigham and Women’s, which will feature more than 80 exam rooms and multidisciplinary clinics, additional infusion spaces, and pharmacy and research space. At Mass General, construction continues on the new Herb Chambers Tower, which will include 228 acute care inpatient beds and 32 ICU beds. At nearly 1 million square feet, it will also be home to a rooftop healing garden and a new center for urgent cancer care, providing 24/7 access to patients. The building is slated to open in 2027.
Mayo Clinic (Rochester, Minn.). The Mayo Clinic Comprehensive Cancer Center is a global leader in cancer care, research and education, serving more than 130,000 people with cancer each year and treating over 200 cancer types. The center is the only NCI-designated comprehensive cancer center with three sites in Arizona, Florida and Minnesota, reflecting its multidisciplinary, collaborative approach to advancing cancer prevention, diagnosis and treatment. For more than 50 years, Mayo Clinic has shaped national cancer research efforts through precision medicine and a focus on individualized, holistic care that addresses patients’ medical, emotional and social needs. Ranked among the top hospitals for cancer care by U.S. News & World Report, Mayo Clinic delivers access to innovative therapies through one of the nation’s most robust clinical trial programs. Its cancer research training and education coordination program develops the next generation of oncology leaders, while the Stephen and Barbara Slaggie Family Cancer Education Center and Community Outreach and Engagement Office extend trusted information and equitable access to care. The center is accredited by the American College of Surgeons’ Commission on Cancer.
MedStar Health (Columbia, Md.). MedStar Health’s MedStar Georgetown Cancer Institute brings together many of the nation’s leading specialists to deliver cancer care for adults and children. Through its partnership with the Georgetown Lombardi Comprehensive Cancer Center, the only NCI-designated comprehensive cancer center in the Washington, D.C. region, patients gain access to the latest treatments, clinical trials and research-driven innovations close to home. The institute offers a full continuum of cancer services, from prevention and screening to advanced therapies, rehabilitation and survivorship programs, all personalized to each patient’s unique diagnosis. Its physicians are board-certified and subspecialized in specific cancer types, providing the expertise and experience associated with improved outcomes. Accredited with commendation by the American College of Surgeons’ Commission on Cancer, MedStar Georgetown Cancer Institute teams empower patients by melding cutting-edge science with human connection.
MemorialCare (Fountain Valley, Calif.). MemorialCare Cancer Institute is a nationally regarded cancer program spanning MemorialCare’s Long Beach Medical Center, Orange Coast Medical Center in Fountain Valley, Saddleback Medical Center in Laguna Hills, and scores of community-based centers. The program has received numerous accolades, including recognition from U.S. News & World Report, Healthgrades and others. MemorialCare Breast Center is among the nation’s first community breast centers with annual screenings of more than 71,000 across 16 locations, with dedicated clinical experts solely focused on breast cancer and treatment. MemorialCare’s history of pioneering innovations in radiation oncology have resulted in novel procedures and advanced, sophisticated technologies that are often first in the region, including the recent opening of the gamma tile study for brain cancer. The MemorialCare lung cancer program is one of a handful in California equipped with the recent FDA-cleared robotic navigated bronchoscopy system, which uses integrated tomosynthesis to locate hard-to-reach lesions in the outer third of the lung. MemorialCare Cancer Institute is one of only two California study sites to offer VAPOR 2 study, a new way to treat prostate cancer that employs water vapor to target and destroy walls of cancer cells while minimizing damage to surrounding healthy prostate tissue.
MemorialCare Miller Children’s & Women’s Hospital (Long Beach, Calif.). Jonathan Jaques Children’s Cancer Institute at MemorialCare Miller Children’s & Women’s Hospital is one of only 10 children’s hospitals in the U.S. to hold full accreditation from the American College of Surgeons Commission on Cancer. It is also a member of Children’s Oncology Group. Its robust psychosocial programs, including school reintegration, help patients and families navigate the cancer journey. It is one of just four sites nationally participating in the National Institutes of Health study called “Bridging Information Divides and Gaps for Equity in Survivorship.” The survivors’ treatment assessment and resource program helps 700 childhood cancer survivors yearly understand and manage late effects of treatment. The bone and soft tissue tumor program focuses on the diagnosis, removal and treatment of benign and malignant bone tumors and soft tissue sarcomas. The highly regarded hematology program sees about 500 patients each year. It is one of the region’s few children’s hospitals with an in-house surgeon specializing in pediatric orthopedics and oncology. Located on the same campus as a highly regarded adult cancer center, the institute is among a select number of children’s hospitals nationwide where patients have access to comprehensive, lifelong care in one convenient location.
Mercy (St. Louis). Mercy health system’s cancer care program includes approximately 300 cancer specialists who diagnose and/or treat 14,800 patients annually at 21 sites, seven of which are accredited by the Commission on Cancer. Mercy was recognized in 2020 and 2024 with the Association of Cancer Care Centers “Innovation Award” for implementing AI powered texting for high-risk cancer patients. Mercy has since expanded this outreach to all adult cancer patients after chemotherapy through a patient-reported outcomes initiative. Through Mercy Research and Cancer Research for the Ozarks, Mercy enrolled 878 patients into 66 oncology research studies and screened over 13,000 others for research eligibility last year. In addition, Mercy’s precision medicine program offers early detection of several cancers with a peer reviewed diagnostic workup. The health system also offers text outreach whereby patients can complete a survey to determine if they are candidates for hereditary cancer testing. Mercy’s clinics in Fort Smith, Ark., and Joplin, Mo., participate in the CMS “Enhancing Oncology” model. Both clinics achieved the maximum scores on quality measures such as emergency department visits and inpatient admissions and ended the fiscal year $1 million below expenditure benchmarks. Earlier this year, Mercy rolled out a care gap analysis for lung and breast cancer patients. This AI platform supports clinicians in delivering guideline-directed care by analyzing EHR data to identify insights that support clinical decision-making, improve patient outcomes and streamline workflows.
Memorial Sloan Kettering Cancer Center (New York City). Memorial Sloan Kettering Cancer Center is internationally recognized for its mission to end cancer for life through excellence in patient care, research and education. Established in 1884, MSK has consistently ranked among the nation’s top two cancer hospitals by U.S. News & World Report for more than 30 years. Its teams deliver care informed by groundbreaking discoveries from the Sloan Kettering Institute, which drives innovation in cancer prevention, diagnosis and treatment. Memorial Sloan Kettering operates one of the largest and most comprehensive clinical trials programs in the country, providing patients access to pioneering therapies often years before they are available elsewhere. The center’s robust translational and clinical research enterprise fosters collaboration among scientists and clinicians to accelerate advances across all cancer types. In addition, the cancer center is deeply committed to training the next generation of oncology leaders, who carry its mission forward worldwide.
Michigan Medicine (Ann Arbor). The University of Michigan Health Rogel Cancer Center is one of the nation’s elite NCI-designated comprehensive cancer centers, recognized for its excellence in cancer research, prevention and patient care since 1991. Consistently ranked the No. 1 cancer program in Michigan and among the best in the U.S. by U.S. News & World Report, the cancer center provides care across all major cancer types, including breast, prostate, blood and gastrointestinal cancers. As a member of the National Comprehensive Cancer Network, its experts help define national standards for oncology care. Home to more than 50 departments across nine University of Michigan schools, Rogel integrates groundbreaking basic, clinical, and population research to develop innovative treatments and improve early detection and prevention. The center also leads three NCI specialized programs of research excellence in leiomyosarcoma, prostate cancer and radiosensitization.
Moffitt Cancer Center (Tampa, Fla.). Moffitt Cancer Center, Florida’s first and only NCI-designated comprehensive cancer center, is internationally recognized for excellence in cancer research, prevention and patient care. As one of just 30 institutions in the National Comprehensive Cancer Network, Moffitt unites top scientists and clinicians to accelerate discoveries that transform cancer treatment. Consistently ranked by U.S. News & World Report and Newsweek among the nation’s best cancer hospitals, Moffitt’s care delivery results in survival rates up to four times higher than national averages. The center maintains continuous accreditation from the American College of Surgeons Commission on Cancer and Magnet recognition for nursing excellence. The center offers programs spanning every major cancer type and aims to prevent, treat and ultimately cure cancer while improving quality of life.
Montefiore Health System (Bronx, N.Y.). Montefiore Einstein Comprehensive Cancer Center has led groundbreaking research and equitable cancer care for more than 50 years. Serving one of the nation’s most diverse populations, the center ensures 80% of its clinical trial participants are from underrepresented groups, which is ten times the national average, across more than 320 active studies. With $69 million in research funding and over 400 publications in 2024, the center’s recent advances include a desensitization program expanding access to first-line chemotherapies, the new Marilyn and Stanley M. Katz Institute for Immunotherapy, and the “Bronx Oncology Living Daily” survivorship initiative. Its innovative “FAST Clinic” has increased early-stage lung cancer detection in the Bronx by more than 40%, while its social determinants of health program connects patients to crucial community resources. As a member of the New York Proton Center, Montefiore Einstein Comprehensive Cancer Center provides advanced proton therapy alongside groundbreaking discoveries in leukemia, metastatic disease and environmental cancer risks.
Mount Sinai (New York City). The Mount Sinai Tisch Cancer Center unites more than 250 cancer specialists, surgeons and researchers to deliver advanced, equitable and comprehensive cancer care. An NCI-designated center, Tisch Cancer Institute received $28.5 million in direct NCI funding and $68.9 million in direct cancer-relevant funding to support groundbreaking research in cancer mechanisms, immunology and prevention. The program encompasses 11 specialized centers of excellence, including blood cancers, breast, pancreatic, thoracic and gynecologic oncology, offering highly coordinated care and access to leading-edge clinical trials. Mount Sinai’s robust community outreach and mobile screening initiatives advance early detection for breast, prostate and colorectal cancers, particularly in underserved populations. The system is developing the new Tisch Cancer Hospital, which is a state-of-the-art, multidisciplinary facility designed to expand access and improve patient-centered outcomes. Mount Sinai is ranked No. 6 nationally for cancer care by U.S. News & World Report for 2025–26 and recognized with Magnet designation and Commission on Cancer accreditation.
NYU Langone Health (New York City). The Laura and Isaac Perlmutter Cancer Center at NYU Langone Health is an NCI-designated comprehensive cancer center recognized among the nation’s top 20 hospitals for cancer care by U.S. News & World Report. Perlmutter delivers integrated, whole-patient cancer care grounded in cutting-edge research and precision medicine. The center’s multidisciplinary teams of oncologists, surgeons and researchers provide access to groundbreaking clinical trials, including advances in immunotherapy, targeted therapy and personalized cell-based treatments. Perlmutter’s molecular oncology center pioneers individualized cancer profiling, enabling real-time treatment adjustments based on each tumor’s genetic makeup. Recent breakthroughs include new therapies for intractable lung and triple-negative breast cancers, a 580-gene diagnostic panel for cancer mutations and AI-supported screening innovations. NYU Langone’s Perlmutter Cancer Center is also accredited with commendation by the American College of Surgeons’ Commission on Cancer.
Nebraska Medicine (Omaha). In collaboration with the University of Nebraska Medical Center, The Fred & Pamela Buffett Cancer Centers are a statewide network of sites providing the most comprehensive cancer care in Nebraska. It includes the state’s only NCI-designated cancer center. The flagship location brings together more than 200 leading specialists and researchers in the same eight-story building that includes 108-bed inpatient beds, a laboratory research tower, imaging, procedural spaces and a multidisciplinary outpatient center. The cancer center has been continuously funded by its support grant from NCI since 1984 and currently has $122 million in total grant dollars awarded. The center offers more than 200 clinical cancer trials. As a recognized leader in CAR T-cell therapy for cancer, the cancer centers recently offered the first fully outpatient CAR T-cell treatment in the state and is now leading a first-of-its-kind clinical trial using allogeneic CAR T-cell therapy for multiple sclerosis treatment.
NewYork-Presbyterian (New York City). NewYork-Presbyterian is home to two NCI-designated cancer centers, Columbia University’s Herbert Irving Comprehensive Cancer Center and Weill Cornell Medicine Meyer Cancer Center. Together, the cancer centers offer patients access to world-class care and groundbreaking research. As the only hospital in New York City with two dedicated cancer centers, NewYork-Presbyterian delivers personalized, multidisciplinary care informed by the latest scientific advances and clinical trials. Expert teams of oncologists, surgeons, radiologists, pathologists, and specialists in cardiology, neurology, oncofertility and mental health collaborate to treat the whole person as well as the cancer. The system provides comprehensive services across Manhattan, Brooklyn, Queens, Westchester and the Hudson Valley, including advanced radiation oncology, immunotherapy, minimally invasive surgery and bone marrow transplantation. Patients benefit from early detection and screening programs, as well as access to novel and targeted therapies developed through Columbia and Weill Cornell’s pioneering research.
Northwestern Medicine (Chicago). The Robert H. Lurie Comprehensive Cancer Center of Northwestern University at Northwestern Memorial Hospital is a nationally recognized leader in oncology, ranked No. 17 in the nation for cancer care by U.S. News & World Report. As an NCI-designated comprehensive cancer center and a founding member of the National Comprehensive Cancer Network, Lurie Cancer Center is distinguished by its “exceptional” NCI rating, which is one of the highest honors in academic oncology. The program treats more than 10,000 new cancer cases annually, uniting multidisciplinary teams of surgical, medical and radiation oncologists to deliver personalized, evidence-based care across Chicago and the surrounding suburbs. Patients benefit from access to advanced modalities such as CAR T-cell therapy, precision medicine, proton therapy and image-guided radiation, alongside robust clinical trials and developmental therapeutics programs. Northwestern Medicine’s integrated approach ensures comprehensive support from diagnosis through recovery, improving outcomes and quality of life for patients.
Norton Healthcare (Louisville, Ky.). At Norton Healthcare, more than 100 subspecialized oncologists and providers offer the full spectrum of care in medical, surgical and radiation therapies. Treatments include advanced immunotherapies such as CAR T, tailored genetic therapies and the latest approaches in cancer care, including minimally invasive robotic surgery, stereotactic radiosurgery and advanced brachytherapy. A state-of-the-art Norton Cancer Institute genomics lab offers highly specialized testing to diagnose and treat cancer more precisely and tailor advanced treatments based on a tumor’s specific genetic composition. Robust research is led by oncologists and providers serving as principal investigators on over 170 clinical trials. Specialists cover tumor-specific subspecialties in breast, dermatology, gastrointestinal, genitourinary, gynecologic, head and neck, hematology, neurologic, orthopedic, sarcoma and connective tissue, and thoracic oncology. Specialists offer behavioral oncology and cancer genetics. Extensive educational, physical and emotional support services include support groups, seminars, art and music therapy, massage therapy, yoga and nutritional counseling available through five Norton Cancer Institute resource centers. Norton Cancer Institute is designated by the American College of Surgeons Commission on Cancer as the only accredited integrated network cancer program in Kentucky.
Norton Children’s (Louisville, Ky.). At Norton Children’s Cancer Institute, children and their families have access to a team of more than 200 specialists including oncologists, surgeons, nurses, therapists, pharmacists, social workers and chaplains. It offers families access to the latest treatments, research and clinical trials. Backed by nearly 60 years of pediatric oncology expertise, the program is one of the oldest continuously accredited cancer programs in the U.S. by the American College of Surgeons’ Commission on Cancer. Patients benefit from Kentucky’s leading multidisciplinary pediatric brain tumor program, one of the nation’s largest sickle cell programs, Kentucky’s only CAR T program for children, and specialized care such as bone marrow transplant, immunotherapy and survivorship support. As a member of the Children’s Oncology Group and the “Beat Childhood Cancer” research consortium, Norton Children’s Cancer Institute provides every child access to cutting-edge treatment protocols and clinical trials that meet high standards in pediatric oncology nationwide. Through its collaboration with the University of Louisville School of Medicine, families also benefit from doctors who are not only caregivers, but also professors and active researchers driving the future of cancer care.
Novant Health (Winston-Salem, N.C.). Novant Health Cancer Institute provides nationally recognized, comprehensive cancer care across 30 locations in North Carolina, including major centers in Charlotte, Winston-Salem and Wilmington. With 197 cancer specialists and 76 dedicated oncology beds, the institute offers cutting-edge treatments such as TrueBeam targeted radiation, theranostics and robotic-assisted surgeries, while serving as one of the first cancer centers in the Carolinas to offer tumor-infiltrating lymphocyte therapy. Accredited by the Foundation for the Accreditation of Cellular Therapy for allogeneic and autologous stem cell transplantation and CAR T-cell therapies, Novant Health is also a leader in immunotherapy and cellular research, conducting hundreds of clinical trials, including the first-in-human CAR T product, “ARD103”. Recognized by U.S. News & World Report in 2025 as “high performing” in multiple cancer specialties, Novant Health Cancer Institute advances patient-centered innovation, expands access to expert care statewide and pioneers programs that improve outcomes while reducing costs, such as its emergency room bypass initiative for oncology patients.
OSF HealthCare (Peoria, Ill.). The OSF HealthCare Cancer Institute is a $237 million facility that opened in February 2024 on the campus of OSF HealthCare Saint Francis Medical Center in Peoria, Ill. It serves as the flagship and provides comprehensive services, including early-access clinical trials, in-house diagnostics, radiation oncology, chemotherapy, surgical oncology and medical oncology. Its robust supportive care offers precision nutrition, financial navigation, tumor-specific cancer navigation, social services, behavioral health, physical therapy, massage, intimacy support and survivorship navigation in one location. The OSF Cancer Institute is only the second in Illinois to provide comprehensive proton therapy, and its brachytherapy surgical suite features a CT scanner on rails for precision treatment of prostate and gynecologic cancers. The OSF Breakthrough Treatment Center provides access to innovative trials, research and early-access therapies. In 2025, the OSF Cancer Institute, long accredited by the American College of Surgeons Commission on Cancer, became the first in the nation to offer a lung cancer early detection blood test. In addition to the flagship cancer center, dedicated cancer centers and clinics at nine other OSF hospitals in Illinois and Michigan provide a range of cancer treatment and support services.
OU Health (Oklahoma City, Okla.). The Stephenson Cancer Center, part of OU Health, the University of Oklahoma academic health system, ensures patients can access research-driven cancer care close to home. As Oklahoma’s only NCI-designated cancer center, it offers clinical trials and multidisciplinary care for patients in all 77 counties. In addition to the Oklahoma City flagship, it includes a 50,000-square-foot site at Norman (Okla.) Regional Hospital and a northeast Oklahoma location partnering with Tulsa, Okla.-based Hillcrest HealthCare System. A new facility is planned for the University of Oklahoma–Tulsa campus, backed by $50 million in public and private funding. Screening programs include a mammography bus supported by MidFirst Bank and a lung cancer screening bus partnered with the Oklahoma Tobacco Settlement Endowment Trust. Nearly 300 early-phase clinical trials are offered annually, with one in five patients enrolled and the state’s only phase 1 program. Researchers are leading over 450 biomedical projects and have published over 2,000 scientific articles in three years, with $60 million in annual funding. The center is advancing the NIH-funded “Route 66 Endometrial Cancer Specialized Program of Research Excellence”, and is partnering with tribal nations to improve outcomes for American Indian and Alaska Native communities with a $17.2 million NIH grant. OU Health was Oklahoma’s first system to use an imaging agent that makes lung tumors glow during surgery, helping surgeons remove cancer more completely while preserving healthy tissue. It earned a three-year accreditation from National Accreditation Program for Rectal Cancer, Oklahoma’s only accredited program and one of just three in a 500-mile radius.
Ochsner Health (New Orleans). For more than 80 years, Ochsner Cancer Institute has been a regional leader in cancer research, treatment and innovation. Treating over 40,000 patients annually from all 50 states and 28 countries, Ochsner takes a collaborative, patient-centered approach powered by multidisciplinary teams of up to 20 cancer specialists per patient. The institute offers some of the most advanced therapies available, including bone marrow and stem cell transplants, CAR T-cell therapy, targeted therapy and immunotherapy. Through its partnership with Houston-based MD Anderson Cancer Center, Ochsner provides access to cutting-edge clinical trials, including early phase 1 studies that pioneer next-generation treatments. Ochsner is accredited by the Commission on Cancer and recognized by U.S. News & World Report as “high performing” in multiple cancer specialties.
The Ohio State University Comprehensive Cancer Center (Columbus). The Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J. Solove Research Institute is the only cancer program in the nation that unites an NCI-designated comprehensive cancer center, a nationally ranked academic health center and a freestanding cancer hospital on a major public university campus. Designated by the NCI since 1976 and rated as its highest distinction, the cancer program integrates pioneering basic, translational and population research with world-class patient care. The 21-story, 358-bed James Cancer Hospital is one of the nation’s largest and has been ranked among the top cancer hospitals by U.S. News & World Report for 26 consecutive years. With over $33 million in NCI support and a strategic focus on immuno-oncology, cancer prevention, survivorship and health equity, the program is both innovative and accessible, offering new patient appointments within five days and statewide access to clinical trials. The center is driven by its mission to create a cancer-free world.
Oregon Health & Science University Hospital (Portland). The OHSU Knight Cancer Institute, an NCI-designated comprehensive cancer center, is internationally recognized for launching novel targeted therapies and advancing the future of precision oncology. The Knight is home to more than 1,400 research projects and over 400 active clinical trials each year. Its team of physicians, scientists and care specialists treat roughly 6,000 patients annually, offering cutting-edge therapies personalized to each individual’s genetics and cancer profile. The Knight’s Cancer Early Detection Advanced Research Center is the world’s leading program dedicated to finding cancer at its earliest, most treatable stages. With the support of a historic $2 billion gift, the institute continues to expand its vision to make clinical trials, innovative care, and comprehensive support accessible for every patient.
Orlando (Fla.) Health. Together, the Orlando Health Cancer Institute and The Haley Center for Children’s Cancer and Blood Disorders form one of Florida’s largest and most comprehensive cancer programs, caring for more than 120,000 patients each year across 21 locations. Accredited by the American College of Surgeons Commission on Cancer as an academic comprehensive cancer program, the institute offers advanced therapies including proton therapy, MRI- and CT-guided adaptive radiation, and cutting-edge cellular treatments such as CAR T and tumor-infiltrating lymphocyte therapy. The Haley Center is Central Florida’s largest pediatric hematology and oncology program and leads the state in pediatric clinical trial participation. Orlando Health’s bone marrow transplant and cellular therapy program, accredited by the Foundation for the Accreditation of Cellular Therapy, is nationally recognized for superior survival outcomes. The institute has 110 active clinical trials, $2 million in annual research funding, and has been named among the top 100 cancer hospitals by U.S. News & World Report for 2025-26.
Penn Medicine (Philadelphia). Celebrating over 50 years as a leader in cancer research, treatment and cures, Penn Medicine’s Abramson Cancer Center has been continuously designated as a comprehensive cancer center by the National Cancer Institute since 1973. It is home to more than 400 basic, translational and clinical scientists who collaborate to transform scientific discoveries into real-world results that improve the prevention, diagnosis and treatment of cancer. Since 2017, Penn Medicine teams have led pioneering work that has resulted in multiple FDA approvals for drugs and techniques to treat cancer, including Kymriah, the first CAR T cell treatment in the world. Thousands of patients globally have benefited from this breakthrough, which has also opened new avenues for treating other diseases. The Abramson Cancer Center includes seven acute care hospitals, a dozen outpatient cancer centers and a growing network of community cancer affiliations, offering comprehensive cancer care throughout the Greater Philadelphia region. Using a unique hub-and-spoke model that brings innovative treatments directly into communities, Penn Medicine operates the Roberts Proton Therapy Center in Philadelphia, along with two community-based proton therapy centers in Lancaster, Pa. and southern New Jersey. Construction is also underway on a fourth proton therapy center at Penn Presbyterian Medical Center, expected to open in 2027.
RWJBarnabas Health and Rutgers Cancer Institute of New Jersey (West Orange and New Brunswick, N.J.). Rutgers Cancer Institute of New Jersey and RWJBarnabas Health together form the state’s only NCI-designated comprehensive cancer center, uniting academic research excellence with statewide access to advanced cancer care. The partnership recently opened the 12-story, 520,000-square-foot Jack & Sheryl Morris Cancer Center, which is New Jersey’s first freestanding comprehensive cancer hospital and one of only 13 in the nation, serving as the cornerstone of a $1.5 billion systemwide oncology expansion. With more than 450 specialists and researchers and over $125 million in annual research funding, the center leads more than 200 clinical trials and conducts transformative studies through five comprehensive research programs. Additional projects, including the forthcoming Melchiorre Cancer Center and the Specialty and Cancer Care Pavilion at the Vogel Medical Campus, further expand access to precision oncology, immunotherapy and clinical trials across the region. Rutgers Cancer Institute and RWJBarnabas Health were recognized by U.S. News & World Report for excellence in cancer care and won the Association of Cancer Care Centers “Innovator Award” in 2024.
Rochester (N.Y.) Regional Health. The Lipson Cancer Institute provides cancer care to over 25,000 patients annually across 13 counties. It offers a full spectrum of treatments and support services, including clinical trials, genetic testing and intraoperative radiation. Through its “Lipson Collaborative Care” program, patients receive personalized counseling and psychological support to help manage anxiety, stress and depression throughout their cancer journey. The institute features advanced, multimodal radiation facilities and offers innovative treatments like bispecific T-cell engagers, a next-generation immunotherapy that guides T-cells to recognize and destroy cancer cells. Now celebrating 40 consecutive years of accreditation by the American College of Surgeons Commission on Cancer, Lipson Cancer Institute is the region’s first and longest-accredited cancer program. As part of its commitment to prevention, the institute also leads “Genowell”, a large-scale community genetic screening initiative aimed at identifying individuals at higher cancer risk and providing timely, proactive care.
Roper St. Francis Healthcare (Charleston, S.C.). Roper St. Francis Healthcare, the region’s largest nonprofit health system, cares for patients with cancer across community-based hospitals and outpatient centers. Nationally recognized for its outcomes, the cancer program treats more solid tumor cases than any other provider in the area. Accredited by the National Accreditation Program for Breast Centers and certified by the American College of Surgeons Commission on Cancer, the system offers a full continuum of services, from advanced intensity-modulated radiation therapy and immunotherapy through the Mott Bone Marrow Transplant and Cellular Therapy Clinic to survivorship support. The system led global enrollment for the FDA-approved OPDIVO lung cancer trial. A designated colorectal epicenter and robotic colorectal training site, Roper St. Francis was the first in South Carolina to combine the da Vinci surgical robot with Firefly technology and has performed more than 1,000 robotic thoracic surgeries with top 1% national outcomes. Its mobile health unit screens hundreds of low-income residents monthly, while the Donna Fielding Wellness Institute and Survivorship Clinic provides personalized support before, during and after treatment.
Roswell Park Comprehensive Cancer Center (Buffalo, N.Y.). Currently rated as “exceptional” by the National Cancer Institute, Roswell Park is regarded as a model for other cancer centers and serves as an innovator in care, prevention, treatment and education. One of the initial three cancer centers specially designated by the NCI as part of the “War on Cancer” in the 1970s, Roswell Park has contributed numerous major advances since its founding in 1898. The cancer center helped establish the effectiveness of cancer chemotherapy, led the discovery of a prostate cancer biomarker and developed the prostate-specific antigen prostate cancer test, implemented photodynamic therapy for cancer, found evidence of smoking’s link to cancer, developed many mainstay cancer treatments, launched one of the first cancer outreach and community engagement programs, and acts as a pioneering resource for Indigenous cancer health. The Roswell Park team’s prominence continues today with pioneering molecular diagnostics, a novel immunotherapy that is helping brain cancer patients beat the odds, and groundbreaking work to make cellular therapy work for more patients. Roswell Park is the only NCI-designated comprehensive cancer center in Upstate New York.
Sanford Health (Fargo, N.D.). A highly regarded regional leader in cancer care for adults and children, Sanford Health’s Roger Maris Cancer Center offers the only blood and bone marrow transplant program in the upper Midwest. It provides access to the latest innovative treatments and clinical trials through its status as a National Cancer Institute community oncology research program and Children’s Oncology Group research site. As a result of its advanced services, the center welcomes 600 patients to its Fargo facility each day, of which nearly 50% travel 60 miles or more to receive care. To support these patients and their families, the center is opening the Peltier Lodge in 2027, offering a convenient place to stay during extended treatments. In addition, Sanford has expanded access through outreach to rural communities with the opening of a Roger Maris Cancer Center facility at Perham (Minn.) Health in 2023 and the addition of its first full-time provider at Sanford Thief River Falls (Minn.) in 2025. Dedicated to improving patient outcomes, the center collaborates closely with primary care providers across the Sanford system to promote early cancer detection, notably contributing to a 16% decrease in late-stage lung cancer diagnoses since 2020.
Scripps Health (San Diego). Scripps Cancer Center, part of Scripps Health, is a nationally recognized, clinically integrated network providing comprehensive cancer prevention, diagnosis, treatment and survivorship care across San Diego County. Scripps Cancer Center treats more than 6,000 patients annually and brings together over 200 oncology specialists in multidisciplinary clinics that ensure personalized, coordinated care. Patients benefit from advanced therapies including robotic and minimally invasive surgery, precision radiation, interventional oncology, and cutting-edge theranostics such as Pluvicto and Lutathera. The program’s robust research portfolio includes $9 million in active and upcoming cancer research funding and 27 clinical trials, while its community outreach initiatives improve access to screening and care among underserved populations. Scripps Cancer Center also boasts exceptional outcomes in bone marrow transplant and theranostics programs, as well as one of the nation’s highest lung cancer screening retention rates. Thanks to its excellence in cancer care and innovation, Scripps has earned national recognition from Newsweek, U.S. News & World Report and other publications.
Sharp HealthCare (San Diego). The Cancer Centers of Sharp HealthCare deliver nationally accredited, patient-centered cancer care across San Diego County, combining advanced technology with multidisciplinary expertise. As an integrated network cancer program accredited by the American College of Surgeons Commission on Cancer, Sharp unites 93 oncology specialists across multiple disciplines to provide seamless, personalized treatment. Sharp is the only health system in San Diego designated a network of excellence in robotic surgery by the Surgical Review Corporation and among the first globally to adopt the da Vinci 5 surgical robot. Through nine multidisciplinary tumor boards and the Sharp Center for Research, one of the nation’s most comprehensive hospital-based research programs with more than 50 active and follow-up clinical trials, Sharp ensures precision care guided by the latest science. Patients benefit from specialized techniques such as robotic-assisted and thermal ablation surgery, Y90 radioembolization and intraarterial chemotherapy, as well as comprehensive cognitive support and survivorship programs.
Siteman Cancer Center at Barnes-Jewish Hospital and WashU Medicine (St. Louis). Siteman Cancer Center at Barnes-Jewish Hospital and WashU Medicine, Missouri and southern Illinois’ only NCI-designated comprehensive cancer center and a National Comprehensive Cancer Network member, is one of the few U.S. centers to earn the NCI’s highest rating of “exceptional.” Treating more than 75,000 adults annually, including 12,000 new patients, Siteman ranks among the top five cancer centers nationally for patient volume. Supported by $185 million in annual research funding, including $66 million from the NCI, Siteman advances more than 1,400 research projects and 1,600 clinical studies each year. Recent milestones include the opening of the Gary C. Werths Building for outpatient care and the Outpatient Cellular Therapy Center, as well as the launch of pioneering AI-based breast cancer risk technology awarded FDA “Breakthrough Device” designation in 2025. With outcomes exceeding national benchmarks across multiple cancers, Siteman combines groundbreaking research, multidisciplinary clinical excellence, and a deep commitment to prevention and equity.
St. Jude Children’s Research Hospital (Memphis, Tenn.). St. Jude Children’s Research Hospital Comprehensive Cancer Center is the first and only NCI-designated comprehensive cancer center devoted solely to children. The center has received the highest ranking of “exceptional” in its two most recent NCI reviews. In 2022, NCI extended its grant funding period based on sustained progress, stability and longevity. The center is organized as five cross-disciplinary, multidepartmental programs aligned to specific diseases and research concepts: developmental biology and solid tumor; neurobiology and brain tumor; hematological malignancies; cancer control and survivorship; and cancer biology. The center also supports 10 core resource laboratories to facilitate research design, implementation, analysis, interpretation and reporting. The center is a member of the Pediatric Cancer Dependencies Accelerator. Through the center, St. Jude aims to improve outcomes and understanding of pediatric cancer to benefit patients and survivors in its catchment area, and to extend these findings to the nation and the world.
Stanford Medicine (Palo Alto, Calif.). The Stanford Cancer Institute, an NCI-designated comprehensive cancer center, integrates compassionate care with pioneering research that advances global understanding of cancer prevention, detection and treatment. Its “Circle of Care” model ensures that each patient receives a personalized, multidisciplinary treatment plan designed by leading surgical, medical and radiation oncologists, additionally supported by specialized nurses, care coordinators and wellness experts. With more than 450 faculty members and over 250 active clinical trials, Stanford is at the forefront of translational research, exploring innovative therapies in areas such as cell therapy, precision medicine and immuno-oncology. The institute’s comprehensive network across Silicon Valley provides convenient access to advanced diagnostics, cutting-edge treatments and digital health tools that enhance patient connection and continuity of care. Stanford’s holistic wellness program encompasses integrative medicine, nutrition, mental health, rehabilitation and spiritual support, addressing the full spectrum of patient needs from diagnosis through survivorship.
Sutter Health (Sacramento, Calif.). Sutter Health’s advanced cancer service line delivers expert, innovative cancer care to more than 120,000 patients annually across 22-plus cancer care sites through a coordinated network of more than 230 oncology physicians and 40 nurse navigators. With a mission to bring world-class care close to home, Sutter integrates prevention, research, advanced treatment and survivorship services across Northern California. Its nine specialized disease site programs of distinction and 52 shared tumor boards ensure standardized, high-quality, multidisciplinary care for every patient, regardless of location. A leader in oncology research, Sutter offers over 150 active clinical trials, including NCI-sponsored studies and advanced therapies such as CAR T-cell therapy and GammaTile. Sutter Health has invested in major projects like AI-driven imaging, expanded clinical access points and upcoming cancer center openings. The system’s excellence is reflected in its Commission on Cancer and National Accreditation Program for Breast Centers accreditations, along with its consistent recognition in U.S. News & World Report rankings.
Tampa (Fla.) General Hospital. The TGH Cancer Institute, part of Tampa General Hospital and its academic partnership with the USF Health Morsani College of Medicine, delivers cancer care grounded in precision medicine and clinical innovation. With more than 50 employed specialists and nearly 300 affiliated providers, the institute treats complex and rare cancers through advanced imaging, genetics, AI and access to groundbreaking clinical trials. Recent milestones include the launch of a cellular-immunotherapy transplant unit expanding CAR T and cellular therapies to outpatient settings, center of excellence designations from the National Pancreas Foundation and GO2 for Lung Cancer, and membership in the elite Sarcoma Alliance for Research through Collaboration. The institute also earned “quality oncology practice initiative” certification from the American Society of Clinical Oncology and maintains Commission on Cancer accreditation. Under the leadership of nationally recognized oncology experts, the institute is working to expand access and health equity across a 15-county region while advancing its goal of achieving NCI designation within the decade.
Temple University Health System (Philadelphia). Fox Chase Cancer Center, part of Temple University Health System, is an NCI-designated comprehensive cancer center and has maintained this prestigious status for 50 years. Founded in 1904 as one of the nation’s first cancer hospitals, Fox Chase has a distinguished legacy of groundbreaking discoveries, including the Philadelphia chromosome, which revolutionized cancer genetics and led to the development of Gleevec. The center continues to lead through more than 500 active research projects supported by $80 million in annual funding and a robust portfolio of 230 clinical trials, nearly half of which are investigator-initiated. Fox Chase was the first cancer hospital in Pennsylvania to achieve Magnet designation for nursing excellence, earning six consecutive renewals. A founding member of the National Comprehensive Cancer Network, Fox Chase pioneers advances in adaptive radiation therapy, precision breast-conserving surgery and novel leukemia treatments.
UC Davis Health (Sacramento, Calif.). UC Davis Comprehensive Cancer Center is the only NCI-designated center serving inland Northern California and reaches a 6-million-person region. The center provides care to more than 100,000 adults and children annually and offers approximately 300 active clinical trials across phases 1–3, including regionwide phase 1 access through the “Sacramento Citywide Oncology Phase I” program. An innovative research enterprise of nearly 260 scientists received over $12 million in cancer-related funding supporting 108 projects in 2024, leveraging collaborations across the school of medicine, medical center, children’s hospital and the Institute of Regenerative Cures. UC Davis uniquely manufactures CAR T-cells on site, making it the only University of California campus to do so, and is working to advance precision therapies such as targeted molecular theranostics. Technology leadership includes developing the world’s first total-body PET scanner, “EXPLORER”, and pairing the Ion robotic bronchoscopy system with Cios Spin 3D imaging, contributing to earlier lung cancer diagnoses. In 2025, researchers moved into the $1 billion Aggie Square innovation district to accelerate translation with industry partners. Equity-focused initiatives span the community outreach and engagement office and the new 45-foot “MobileMammo+” program for rural screening, while a comparative oncology program with the nation’s top veterinary school drives translational trials in companion dogs to inform human cancer care.
UC San Diego Health. UC San Diego Health’s Moores Cancer Center is the only NCI-designated comprehensive cancer center in San Diego, and is ranked among the top 50 cancer programs in the nation by U.S. News & World Report, holding the No. 41 spot for 2025–26. As an international leader in cancer care and research, the center’s oncologists set treatment standards nationwide for more than 200 cancer types, offering patients personalized, evidence-based therapies with superior outcomes. UC San Diego Health provides access to a wide range of clinical trials, allowing patients to benefit from breakthrough treatments before they become widely available. The cancer center emphasizes whole-person care through a robust network of supportive services, including counseling, integrative therapies, and financial and rehabilitation support.
UCHealth (Aurora). Celebrating its 40th anniversary in 2025, UCHealth’s University of Colorado Cancer Center is the only NCI-designated comprehensive cancer center in Colorado and the Rocky Mountain region. The center unites more than 270 experts to deliver compassionate, multidisciplinary cancer care informed by groundbreaking research and innovation. With over $74 million in annual direct funding and more than 80 NCI grants, CU Cancer Center scientists are advancing discoveries that translate rapidly into new treatments and technologies. Patients benefit from access to clinical trials offering tomorrow’s therapies today and coordinated treatment plans shaped by teams of more than 30 subspecialists. Recognized by U.S. News & World Report for excellence in survival outcomes, technology and patient experience, the CU Cancer Center sets national standards for cancer prevention, treatment and education.
UCI Health (Orange, Calif.). The UCI Health Chao Family Comprehensive Cancer Center, Orange County’s only NCI-designated comprehensive cancer center, delivers world-class, patient-centered cancer care powered by leading-edge research and innovation. Each patient receives individualized treatment from a multidisciplinary team specializing in their specific cancer type, ensuring the most advanced and effective therapies available. Patients benefit from dedicated nurse navigators and an integrative supportive care team, including dietitians, social workers and holistic medicine experts, all focused on improving quality of life throughout treatment. One of the region’s largest clinical trial programs gives patients access to groundbreaking therapies for both common and rare cancers. Recognized by U.S. News & World Report and the American Society of Clinical Oncology, UCI Health is also a Blue Distinction Center for complex and rare cancers.
UCLA Health (Los Angeles). The UCLA Health Jonsson Comprehensive Cancer Center, an NCI-designated comprehensive cancer center since 1976, is home to more than 500 scientists and physicians driving innovation in cancer prevention, diagnosis and treatment. The center earned 2024 accreditation from the American College of Surgeons’ Commission on Cancer, underscoring its commitment to multidisciplinary, patient-centered care. The center’s research has contributed to 22 FDA approvals for new cancer therapies since 2014 and supports more than 400 active clinical trials. Recent breakthroughs include a novel cancer vaccine targeting key oncogenic mutations, AI tools that improve early breast cancer detection and the launch of one of the nation’s largest outpatient theranostics centers for advanced prostate, thyroid and neuroendocrine cancers. UCLA investigators have also advanced CAR natural killer T cell therapy, an off-the-shelf immunotherapy for ovarian cancer, and demonstrated the benefits of advanced MRI-guided active surveillance for prostate cancer. The center is consistently ranked among the nation’s best hospitals for cancer care by U.S. News & World Report.
UCSF Health (San Francisco). The UCSF Helen Diller Family Comprehensive Cancer Center at UCSF Health delivers personalized, innovative care across nearly 50 cancer clinics spanning more than a dozen specialties throughout the Bay Area. The first in the region to receive the National Cancer Institute’s prestigious “comprehensive” designation, the center integrates advanced research, clinical excellence, and compassionate support for patients and caregivers. Ranked No. 7 nationally and the top cancer program in California by U.S. News & World Report, UCSF Health is among the leading recipients of NCI research funding, driving progress in immunotherapy, molecularly targeted therapies and minimally invasive surgical techniques. Its multidisciplinary teams collaborate to develop individualized treatment plans that improve outcomes and quality of life for patients with all cancer types. UCSF Health has been accredited by the American College of Surgeons’ Commission on Cancer since 1933.
UF Health (Gainesville, Fla.). The UF Health Cancer Center unites leading-edge research and patient care in a collaborative, multidisciplinary environment, serving as the only NCI-designated cancer center based at a public university in Florida. Home to more than 350 researchers and clinicians across the University of Florida and UF Health, the institute is dedicated to preventing, detecting, treating and ultimately curing cancer while addressing the unique needs of Florida’s largely rural population. UF Health offers access to the latest medical research and technologies, including proton therapy, intraoperative radiation therapy, and minimally invasive surgical and interventional oncology techniques. The center has pioneered innovations such as chemical embolization for lung tumors, the Intrabeam system for early-stage breast cancer and the world’s first multidisciplinary metastatic disease program. With $74 million in cancer research funding, UF Health leads translational discoveries, bringing scientific breakthroughs directly to patients for improved outcomes and quality of life.
UK HealthCare (Lexington, Ky.). The UK Markey Cancer Center, Kentucky’s only NCI-designated comprehensive cancer center, is dedicated to creating a cancer-free tomorrow through world-class research, advanced treatment and compassionate care. Recognized by U.S. News & World Report as a “Best Hospital for Cancer” since 2017, Markey offers state-of-the-art, personalized care led by multidisciplinary teams of oncologists, surgeons, radiologists, genetic experts and supportive care specialists. Through its molecular tumor board, Markey tailors therapies to each patient’s genetic profile and connects them to early-phase clinical trials offering promising new treatments. With more than 300 clinical trials and research studies, Markey provides Kentuckians access to groundbreaking therapies unavailable elsewhere in the region. Its team-based approach ensures every patient receives coordinated, individualized care focused on improving survival and quality of life.
UNC Health (Chapel Hill, N.C.). The UNC Lineberger Comprehensive Cancer Center, based at the University of North Carolina at Chapel Hill, is the only public NCI-designated comprehensive cancer center in North Carolina and is rated “exceptional,” the highest category awarded by the NCI. Serving patients through the N.C. Basnight Cancer Hospital, UNC Lineberger unites world-class physicians and scientists across more than 40 departments to advance cancer prevention, detection and treatment. Its research spans the full spectrum, ranging from genetic and environmental studies to groundbreaking clinical trials and community-based cancer prevention programs. With strong support from the state of North Carolina and the University Cancer Research Fund, the center fosters collaboration among leading experts from medicine, pharmacy, public health, nursing and dentistry. UNC Lineberger is also focused on training the next generation of oncology leaders.
UNM Health System (Albuquerque, N.M.). The University of New Mexico Comprehensive Cancer Center is the official cancer center of New Mexico and the only NCI-designated comprehensive cancer center within a 500-mile radius. With 136 board-certified oncology specialists and more than 600 cancer care professionals, the center provides treatment for 65% of New Mexico’s cancer patients across the state. In 2024, the center treated over 15,000 patients through 105,000 clinic visits and enrolled more than 2,000 patients in clinical trials. Its 123 research scientists secured $38.3 million in annual grants and contracts, advancing work in cancer genomics, prevention and novel therapies. The UNM Cancer Center also partners with Sandia and Los Alamos National Laboratories, Lovelace Respiratory Research Institute and New Mexico State University to drive innovation in areas like nanotechnology, drug discovery and radioisotope therapy. Through statewide clinical partnerships and pioneering initiatives such as New Mexico’s first theranostics program, the center is transforming cancer care, research and health equity for the region’s diverse populations.
UPMC (Pittsburgh). UPMC Hillman Cancer Center, western Pennsylvania’s only NCI-designated comprehensive cancer center, has held its designation since 1990 and earned an “exceptional” rating. With more than 2,000 physicians, researchers and staff across 70 locations in four states and five international sites, Hillman treats over 171,000 patients annually. The center is internationally recognized for pioneering innovations in cancer biology and treatment, including the world’s first positron emission tomography-CT scanner, early breakthroughs in immunotherapy using natural killer cells, and the discovery of two of the seven known cancer-causing viruses. UPMC Hillman leads one of the nation’s largest stem cell transplant programs, performs more than 2,000 hyperthermic intraperitoneal chemotherapy procedures, and was the first in western Pennsylvania to offer FDA-approved CAR T-cell therapy, now with six approved products. Researchers are advancing the frontiers of immunotherapy, radiotherapy and cancer prevention, with nearly 400 clinical trials supported by $69.5 million in annual research funding. Guided by a commitment to equity, innovation and community impact, UPMC Hillman’s outreach and prevention efforts have saved an estimated $1.4 billion in healthcare costs.
UR Medicine (Rochester, N.Y.). The University of Rochester’s Wilmot Cancer Institute is the 73rd center in the nation to earn designation from the National Cancer Institute, recognizing its excellence in research, patient care and community impact. Serving more than 3.2 million people across 27 counties in Western and Central New York, Wilmot combines world-class cancer treatment with groundbreaking research through its three programs: genetics, epigenetics and metabolism; cancer microenvironment; and cancer prevention and control. With over 114 research members and $30 million in annual direct funding, Wilmot’s discoveries have advanced global oncology, including its pivotal role in developing the HPV cancer vaccine and anti-nausea therapies that improved cancer treatment adherence. As part of the University of Rochester Medical Center and Strong Memorial Hospital, Wilmot operates 13 clinical care locations and an 88-bed hospital offering specialized services such as one of New York’s largest blood and marrow transplant programs and one of the nation’s first geriatric oncology clinics. Looking ahead, Wilmot is expanding its research facilities, drug development initiatives and patient care networks to continue delivering innovative, life-saving cancer care.
UT Health San Antonio (Texas). UT Health San Antonio MD Anderson Cancer Center, part of the University of Texas Health Science Center at San Antonio, is the only NCI-designated cancer center in Central and South Texas. Established in 1974, the center combines world-class research, education and clinical excellence to serve the diverse cancer care needs of the South Texas community. Through its partnership with Houston-based MD Anderson Cancer Center, patients have access to the same advanced therapies and clinical expertise found at one of the nation’s top cancer programs. The center leads pioneering research in cancer drug development and offers extensive clinical trial opportunities, including first-in-human studies of promising new treatments. The program provides multidisciplinary teams, state-of-the-art facilities, and a focus on prevention and wellness.
UT Southwestern Medical Center (Dallas). The Harold C. Simmons Comprehensive Cancer Center at UT Southwestern Medical Center is North Texas’ only NCI-designated comprehensive cancer center and one of just five in the Southwest. Ranked among the nation’s top 20 hospitals for cancer care by U.S. News & World Report, Simmons Cancer Center unites more than 280 members across 37 departments, advancing cancer prevention, diagnosis and treatment via research and patient-centered care. With 535 active clinical trials and more than 2,000 trial accruals in 2024, the center is also one of only 32 NCI-designated National Clinical Trials Network lead academic participating sites in the U.S. Its 15 multidisciplinary teams of specialists collaborate across disciplines to translate groundbreaking science into new therapies for cancers of all types. Supported by $119.7 million in total research funding, including $34.3 million in direct NCI support, Simmons Cancer Center delivers innovative therapies, cutting-edge technology and comprehensive supportive care.
UVA Health (Charlottesville, Va.). UVA Comprehensive Cancer Center, Virginia’s first and only NCI-designated comprehensive cancer center, is a nationally recognized leader in cancer care, research and prevention. Serving more than 3.2 million residents across 87 counties in Virginia and parts of West Virginia, UVA combines holistic care with world-class innovation. With more than 250 faculty from six UVA schools and $82 million in annual research funding, the center has driven a nearly 500% increase in clinical research participation over the past decade. UVA was among the first 25 U.S. centers to offer MRI-guided radiation therapy and now provides outpatient CAR T therapy and autologous transplants. The center’s experts are advancing treatments for prostate, lung and nerve sheath tumors, while expanding cancer prevention through partnerships with federally qualified health centers to improve screening access across rural regions. UVA Comprehensive Cancer Center is ranked No. 1 in Virginia for cancer care by Newsweek thanks to its commitment to discovery, innovation and equity in oncology.
UW Health (Madison, Wis.). UW Health | Carbone Cancer Center, Wisconsin’s only NCI-designated comprehensive cancer center, has been a national leader in cancer discovery, innovation and care for more than 50 years. Established in 1973 as one of the first six NCI-designated centers, Carbone sees more than 30,000 patients annually and leads over 250 active clinical trials. Its legacy includes pioneering achievements such as the development of Mohs surgery, the discovery of 5-fluorouracil and tamoxifen, and Nobel Prize-winning research that transformed cancer biology. Today, Carbone continues this tradition of innovation through its precision medicine molecular tumor board, the program for advanced cell therapy, and new initiatives in theranostics and particle therapy. In 2024, the opening of Eastpark Medical Center, which is the largest new medical facility in the U.S., introduced groundbreaking technologies such as proton beam therapy. With $125 million in annual research funding, Carbone translates scientific breakthroughs into personalized treatments that improve survival and reduce side effects.
University of Alabama at Birmingham. The O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham is the only NCI-designated comprehensive cancer center in a four-state region. With more than 400 physicians and researchers serving over 10,000 new patients annually, the center leads transformative advances in cancer prevention, treatment and clinical research. Between 2020 and 2024, the center nearly doubled its clinical trials faculty and expanded infrastructure through a $1.5 million investment, resulting in a 50% increase in patient enrollment and more than 200 active oncology trials. In 2025, the launch of the Academic Research Organization for Clinical Trials further streamlined study operations across UAB’s schools. UAB O’Neal has shaped national cancer policy and championed federal research investment, while maintaining a strong regional focus on access and health equity. Recent innovations include the launch of a Saturday infusion clinic, an online second-opinion platform and initiation of tumor-infiltrating lymphocyte therapy for melanoma. Supported by $71.1 million in research and training funding, the O’Neal Cancer Center continues to advance discovery and accelerate access to cutting-edge therapies.
University of Arizona Cancer Center (Tucson). The only NCI-designated comprehensive cancer center headquartered in the state, the University of Arizona Cancer Center is part of Banner–University Medical Center Tucson. With two sites and nearly 40,000 treatment encounters in 2024, it is ranked the top cancer center in Tucson by U.S. News & World Report and is the only accredited breast cancer center in Tucson and one of just three in all of Arizona. It is among the state’s highest-performing cancer surgical intervention facilities and a leading hospital for providing leukemia, lymphoma and myeloma surgery, as well as colon, lung, uterine and prostate cancer surgery. Hundreds of doctors, scientists, postdoctoral fellows, graduate and undergraduate students, and technicians work in more than 70 research laboratories in the University of Arizona Cancer Center. A bedrock of the center is its research, which advances understanding of the fundamental molecular and cellular mechanisms of cancer initiation and progression, taking basic information about cancer cell targets to develop leads for cancer treatment. Research at the University of Arizona is bringing new technologies for cancer imaging to the forefront and also addressing populations at increased risk of developing cancer. There are 265 active clinical trials at the cancer center. In 2024, the program published 194 peer-reviewed research articles.
University of Chicago Medicine. The UChicago Medicine Comprehensive Cancer Center, Illinois’ only NCI-designated comprehensive cancer center, is recognized as the state’s top cancer program and a national leader in oncology innovation. The program includes approximately 150 oncology specialists and treats patients across 20 locations, with 80 inpatient oncology beds at its flagship hospital. UCM is among the nation’s top three programs for tumor-infiltrating lymphocyte therapy and was the first health system in Illinois to treat patients using histotripsy. Its research partnership with Argonne National Laboratory applies AI to develop therapies for drug-resistant cancers, while the new Center to Eliminate Cancer Inequity unites researchers, clinicians and community leaders to address persistent disparities in cancer outcomes. The system recently broke ground on Illinois’ first freestanding cancer pavilion, a patient-centered facility supported by major philanthropic gifts from the AbbVie Foundation and Susan and Tandean Rustandy. Ranked No. 12 nationally by U.S. News & World Report for cancer care and awarded $83.8 million in research funding in 2024, UCM is advancing precision medicine, value-based oncology and national network expansion through new affiliates such as AdventHealth Cancer Institute Shawnee Mission.
University Hospitals (Cleveland). University Hospitals Seidman Cancer Center, part of the NCI-designated Case Comprehensive Cancer Center, is also one of 33 National Comprehensive Cancer Network member institutions. As the only freestanding cancer hospital in Northeast Ohio and one of just 13 in the U.S., UH Seidman provides advanced, patient- and family-centered care through a network of 17 community-based centers. With over 1,100 oncology professionals, including 150 physicians, UH Seidman offers access to more than 400 active clinical trials and nearly $36 million in annual research funding. Its Wesley Center for Immunotherapy is among the few sites nationwide producing CAR T-cell and natural killer cell therapies in-house, enabling ultra-fast manufacturing and rapid access to novel treatments. Ranked among the nation’s top 50 hospitals for cancer care by U.S. News & World Report, UH Seidman leads innovation through cutting-edge radiation technologies, pioneering clinical research and a steadfast commitment to quality, safety and equitable access.
University of Iowa Health Care (Iowa City). The Holden Comprehensive Cancer Center is Iowa’s only NCI-designated comprehensive cancer center, dedicated to reducing the pain and suffering caused by cancer through research, clinical excellence and education. With a mission to make cancer care deeply personal, Holden’s multidisciplinary oncology groups bring together experts across specialties to tailor care to each patient’s unique biological and emotional needs. Its teams specialize in precision medicine, developing and applying DNA-based therapies that target each patient’s cancer at the molecular level. In addition to world-class medical treatment, Holden emphasizes holistic care through its behavioral oncology clinic, genetic counseling, nutrition programs and supportive services. The center holds multiple accreditations, including from the NCI, the American College of Surgeons Commission on Cancer, and the National Accreditation Program for Breast and Rectal Cancer.
University of Kansas Health System (Kansas City). The University of Kansas Cancer Center is the only NCI-designated comprehensive cancer center in Kansas, upholding a standard of excellence in cancer research, prevention and patient care. With more than 350 researchers and 150 disease-specific oncologists, the center provides unmatched expertise in treating all forms of cancer, from the most common to the rarest. As part of an academic medical system, it bridges laboratory discoveries and clinical practice, offering patients early access to groundbreaking therapies and clinical trials. Patients treated here experience a 25% greater chance of survival than at non-NCI-designated centers, reflecting the impact of its research and innovation. With 13 care locations across the region and a robust network of nurse navigators, the center emphasizes compassionate, personalized care that treats the whole person. U.S. News & World Report ranks its cancer program among the nation’s best.
University of Maryland Medical System (Baltimore). The University of Maryland Medical System delivers statewide cancer care through six integrated cancer centers and about 120 specialists. At the network’s core, the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center is an NCI-designated comprehensive cancer center ranked among the nation’s top 50 for cancer, supported by $137 million in annual research funding and 462 clinical trials. The center leads nationally in equity, with minorities comprising 56% of clinical trial enrollment, and has been among the first U.S. programs certified for CAR T-cell therapy. Its investigators also pioneered a first-in-nation approach to cross the blood–brain barrier and deliver therapeutics directly to the brain. Across the system’s community cancer centers, patients access the same innovations, subspecialty expertise and accreditations that underpin high performance in multiple cancer surgeries. The cancer center’s clinical footprint includes 56,000 annual outpatient visits, 1,290 inpatient admissions and 3,100 new patients.
University of Miami Health System. Part of the University of Miami Health System and Miller School of Medicine, Sylvester Comprehensive Cancer Center is South Florida’s only NCI-designated cancer center and one of only five cancer centers of excellence in Florida. Home to more than 3,100 physicians, researchers and staff, Sylvester delivers personalized, research-driven care and conducts over 430 active clinical trials to advance prevention, diagnosis and treatment. Recognized by U.S. News & World Report as a “high performing” cancer center, Sylvester ranks among the nation’s top 50 for cancer care and is acclaimed for its excellence in leukemia, lymphoma, myeloma and multiple surgical specialties. As the only South Florida center offering a phase 1 clinical trials program, Sylvester provides access to the latest investigational therapies and pioneering technologies such as MRI-guided therapy systems and Gamma Knife radiosurgery. With comprehensive survivorship programs and a strong focus on prevention and community health, Sylvester continues to reduce the human burden of cancer.
The University of Texas MD Anderson Cancer Center (Houston). The University of Texas MD Anderson Cancer Center ranks as one of the world’s most respected centers devoted exclusively to cancer patient care, research, education and prevention. The institution has invested $1.3 billion in research across the cancer spectrum and is home to the world’s largest cancer clinical trials program, with over 10,000 clinical trial participants last year. In May, the institution announced a transformational $150 million gift from Kinder Foundation to create Kinder Children’s Cancer Center, a joint venture of UT MD Anderson and Houston-based Texas Children’s, with a single mission to end childhood cancer. This year, MD Anderson maintained its 5-star rating in Vizient’s 2024 “Quality and Accountability” scorecard, was again named the top hospital for oncology in Newsweek‘s 2025 “World’s Best Specialized Hospitals” rankings and again ranked the No. 1 hospital for cancer care by U.S. News & World Report for the eleventh consecutive year.
University of Utah Health (Salt Lake City). Huntsman Cancer Institute at the University of Utah is the only NCI-designated comprehensive cancer center in the Mountain West, serving patients across Utah, Idaho, Montana, Nevada and Wyoming, which is the largest geographic region covered by any NCI-designated center. As the state of Utah’s official cancer center, Huntsman combines world-class research and compassionate care to reduce the burden of cancer and improve outcomes for all communities. Home to more discoveries of inherited cancer genes than any other cancer center worldwide, Huntsman leads groundbreaking genetic and clinical research while offering more than 300 open clinical trials, including the region’s largest and most comprehensive phase I program. The program launched the “Huntsman at Home” initiative, which is the world’s first hospital-level cancer care program delivered in the home. With multidisciplinary teams, community partnerships and expansion through new clinics in Vineyard and West Valley, Huntsman Cancer Institute advances its vision of a future free from cancer.
VCU Health (Richmond, Va.). Founded in 1974, VCU Massey Comprehensive Cancer Center is one of only two NCI-designated comprehensive cancer centers in Virginia and ranks among the top 4% of cancer centers nationwide. As the only NCI-designated center in the Richmond metropolitan region, Massey is a leader in advancing equitable cancer research, prevention and care through community-informed collaboration and groundbreaking science. The center is nationally recognized for its strengths in translating research discoveries into innovative treatments and for its leadership in addressing cancer disparities to ensure equal access to high-quality care. Massey offers the largest portfolio of clinical trials in Virginia, supported by a statewide network that brings cutting-edge therapies to patients across the Commonwealth. With the state’s most comprehensive bone marrow transplant program and a multidisciplinary approach to care, Massey delivers personalized treatment while training the next generation of cancer researchers and clinicians.
Valley Health (Winchester, Va.). Valley Health Cancer Center, part of the Valley Health system, delivers comprehensive, high-quality cancer care to patients across Virginia and West Virginia through an expert multidisciplinary team and state-of-the-art technology. Accredited by the Commission on Cancer, the National Accreditation Program for Breast Centers and the National Accreditation Program for Rectal Cancer, Valley Health exemplifies excellence in oncology. The center’s advanced capabilities include two Varian TrueBeam linear accelerators, the Ion robotic bronchoscopy system for early lung cancer detection, and pulsed electric field ablation, a cutting-edge, non-thermal tumor treatment pioneered in Virginia. The center’s commitment to safety and quality is reflected in a 0% surgical site infection rate for breast and colorectal surgeries in 2024 and exemplary rankings in national surgical outcomes. Supported by the Wellspring Cancer Resource Center, patient navigation services and community-driven funding, Valley Health helps patients thrive through survivorship and holistic support.
Vanderbilt University Medical Center (Nashville, Tenn.). Vanderbilt-Ingram Cancer Center, part of Vanderbilt University Medical Center, is the only NCI-designated comprehensive cancer center in Tennessee that provides care for both adults and children. Recognized by U.S. News & World Report as a top-performing cancer hospital, Vanderbilt-Ingram serves more than 49,000 distinct patients and manages over 250,000 outpatient visits annually. With a team of more than 200 cancer specialists and over 300 physician-scientists, the center leads in precision medicine and translational research, supported by more than $150 million in total research funding, including $69 million in competitive NCI grants. Vanderbilt-Ingram offers access to more than 350 clinical trials and is the developer of MyCancerGenome.org, a globally recognized resource for genetically informed cancer care. As a member of the National Comprehensive Cancer Network, Vanderbilt-Ingram helps shape national standards in cancer prevention, treatment and survivorship care.
WVU Medicine (Morgantown, W.Va.). The WVU Cancer Institute is West Virginia’s leading cancer program, delivering research-driven care across 18 sites with approximately 185,000 clinic visits and 146,000 infusion visits annually. The institute offers the state’s only transplant and cellular therapy, hyperthermic intraperitoneal chemotherapy and Gamma Knife programs, plus one of the nation’s highest-volume robotic pancreas surgery programs. Backed by a transformational $50 million state investment, the institute is expanding infrastructure and research as it pursues NCI designation while growing a trials portfolio that has cut time-to-enroll by more than half and increased accruals by over 500%, including enrolling the first U.S. patients on pivotal breast cancer and acute leukemia studies. Its nationally recognized mobile early-detection fleet brings lifesaving screening to rural Appalachia, alongside partnerships that extend infusion and oncology services to critical access hospitals. The “CHATS Lab” translates evidence into plain-language health messaging to improve outcomes and equity across underserved communities. Innovation spans bench to bedside, from an NCI-funded high-resolution positron emission tomography/CT for hard-to-image head and neck cancers to rapidly expanding precision surgery, systemic therapies and advanced radiation. In 2024, WVU Cancer Institute investigators received $9.6 million in research awards and the program earned multiple national accreditations.
Yale New Haven (Conn.) Health. Yale Cancer Center, in partnership with Smilow Cancer Hospital, has been a leader in cancer research, prevention and care for 50 years. The center is an NCI-designated comprehensive cancer center, the only one in Connecticut. This collaboration between Yale School of Medicine scientists and Smilow Cancer Hospital physicians integrates pioneering research with compassionate, multidisciplinary patient care. Through 13 specialized clinical centers, patients receive highly coordinated, personalized treatment led by expert teams that include physicians, nurse coordinators and intake specialists focused on every aspect of the cancer journey. Yale’s six major research programs unite leading investigators across disciplines to advance discoveries in cancer biology, immunotherapy and molecular oncology, translating breakthroughs directly from bench to bedside. The center brings rapid access to novel therapies through clinical trials and a strong commitment to community engagement and health equity.
